Shanghai Medicilon Inc.

  Medicilon, a one-stop pharmaceutical preclinical research and development CRO can simultaneously meet Chinese and American drug discovery and development needs (including GLP standards ) promptly and efficiently with fast initiation times. Over the past 20 years, Medicilon has been involved in the development of 421 new drug and generic drug projects that have obtained IND approvals to initiate clinical trials. At this time, Medicilon officially appoints Dr. Qingcong Lin as President of Medicilon USA Corp, a significant step to deepen its global and strategic layout. Effective March 1, 2024, Medicilon appointed Dr. Qingcong Lin as President of Medicilon USA Corp in Boston. By integrating top international R&D resources, Dr. Lin will lead Medicilon to explore new paradigms in cutting-edge fields, drive Medicilon to achieve broader and deeper cooperation globally, and empower drug innovations. Dr. Qingcong Lin holds a Ph.D. in Molecular Biology from the Albert Einstein College of M

On February 19, SIBP-A17, the second class I innovative antibody drug conjugate (ADC) independently developed by China National Pharmaceutical Group's Shanghai Institute of Biological Products, received a clinical trial approval notice from the National Medical Products Administration (NMPA).  The SIBP-A17 is intended for clinical trials in patients with advanced malignant solid tumors. Shanghai Medicilon Inc. (Medicilon), as a partner of Shanghai Institute of Biological Products, provides preclinical research services such as pharmacokinetics and safety evaluation for the research and development of SIBP-A17.  This is another successful case of Medicilon helping the rapid implementation of research and development results in the ADC field. Medicilon Antibody Drug Conjugate R&D Service Platform One-Stop Service Promotes Efficient Drug Research and Development Honest innovation drives the Shanghai Institute of Biological Products to continuously upgrade its products, and also dr

  Preclinical research for inhaled formulations is the stage in which inhaled formulations are comprehensively evaluated and validated prior to clinical trials.  Key research can be conducted including drug characteristics evaluation, atomization performance evaluation, animal pharmacokinetics and toxicity studies, stability studies and toxicology evaluation.  The goal of preclinical research on inhaled preparations is to fully understand the performance, safety and effectiveness of inhaled preparations, provide scientific basis for subsequent clinical trials, and ensure the quality and efficacy of inhaled preparations in clinical applications. Currently, Medicilon can provide a complete safety evaluation of inhaled preparations (pharmacokinetics, toxicokinetics, safety pharmacology, toxicology, reproductive toxicology) and has accumulated a lot of experience in the development of inhalation preparations for many years.  Before the test, a preliminary exploration of particle size, conc

  On January 26, SYN045, a Class I new drug developed by Shijiazhuang No.4 Pharmaceutical, received a clinical trial approval notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).  This marks another substantial step forward in the research and development of the company's second innovative drug. Shanghai Medicilon Inc. (Medicilon), as a partner of Shijiazhuang No.4 Pharmaceutical, provided preclinical research services such as pharmacokinetics and safety evaluation for the development of SYN045 tablets, helping to successfully obtain approval. SYN045 is a Class I new drug independently developed by Shijiazhuang No.4 Pharmaceutical.  SYN045 is a selective long-acting PGI2 receptor agonist and is intended to be used for pulmonary arterial hypertension.  Preclinical studies have shown that SYN045 has good target selectivity, compound activity, and safety. Currently, Medicilon's preclinical research service platform has establishe

  In 2024, Medicilon will celebrate its 20th anniversary.  At the time of departure, Medicilon shouldered the dream of China's new drug research and development, took root in Zhangjiang, Shanghai, and embarked on a long journey to pursue the dream.  During the past 20 years, Medicilon has transformed into a leading one-stop biopharmaceutical preclinical R&D service CRO in China, and is moving forward with its goal of being a world-class CRO. From chemical drugs to bi/multi-specific antibodies,  ADCs ,  nucleic acids ,  mRNA ,  PROTAC ,  CGT  and other fields, Medicilon continue to move towards the forefront of technology.  From the initial provision of chemical services to one-stop biopharmaceutical preclinical R&D services, Medicilon continue to expand the services.  From 0 to 420 IND approvals, Medicilon helps customers complete new drug clinical trial applications from China NMPA, US FDA, EU EMEA and Australia TGA.  These include the world's first inhaled nanobody dr